These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29064576)

  • 1. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis.
    Alves da Silva R; de Souza Todão J; Kamitani FL; Silva AEB; de Carvalho-Filho RJ; Ferraz MLCG; de Carvalho IMVG
    J Med Virol; 2018 Mar; 90(3):537-544. PubMed ID: 29064576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.
    Cuypers L; Li G; Libin P; Piampongsant S; Vandamme AM; Theys K
    Viruses; 2015 Sep; 7(9):5018-39. PubMed ID: 26389941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China.
    Jia Y; Yue W; Gao Q; Tao R; Zhang Y; Fu X; Liu Y; Liu L; Feng Y; Xia X
    Microbiol Spectr; 2021 Sep; 9(1):e0029721. PubMed ID: 34479413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
    Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
    Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping hepatitis C virus from hemodialysis patients in Central Brazil by line probe assay and sequence analysis.
    Espírito-Santo MP; Carneiro MA; Reis NR; Kozlowski AG; Teles SA; Lampe E; Yoshida CF; Martins RM
    Braz J Med Biol Res; 2007 Apr; 40(4):545-50. PubMed ID: 17401498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Viral C hepatitis in patients with end stage renal disease. II. Viral genotypes].
    González-Michaca L; Mercado A; Gamba G
    Rev Invest Clin; 2000; 52(5):491-6. PubMed ID: 11195176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia.
    Lopez-Osorio MC; Usme-Ciro JA; Martínez JW; Peláez-Carvajal D; Hernández J; Hoyos S; Restrepo JC; Navas MC
    Virus Res; 2022 Sep; 318():198847. PubMed ID: 35697300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6.
    Ju W; Yang S; Feng S; Wang Q; Liu S; Xing H; Xie W; Zhu L; Cheng J
    Virol J; 2015 Jul; 12():109. PubMed ID: 26206422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis.
    Wu Z; Cui L; Zhao W; Yang D; Chen H; Wang R; Wang X; Zhang L; He T
    Virol J; 2016 Oct; 13(1):172. PubMed ID: 27756381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.